Wuhan EasyDiagnosis Biomedicine Co., Ltd, was founded in 2008 and is located at the National Biological Industry Base of Bio-Lake in Wuhan Optical Valley. As a new high-tech enterprise specializing in products related to in vitro diagnostic reagents and auxiliary apparatuses (POCT/molecular diagnosis/chemiluminescence/blood gas analysis etc.), Wuhan EasyDiagnosis is playing a leading role in Chinese domestic high through-put POCT products and serves as a prominent enterprise in the IVD industry. With our businesses covering more than 5,000 medical institutes in China and our sales network covering more than 35 countries and regions in Asia, Europe, South Africa, Africa, etc., Wuhan EasyDiagnosis is now a listed company (Shenzhen Stock Exchange) with the stock code of 002932. During the combat against COVID-19, Wuhan EasyDiagnosis successfully developed COVID-19 SARS-CoV-2 Nucleic Acid Test Kit and registered with NMPA in March. Now, the COVID-19 SARS-CoV-2 Nucleic Acid Test Kit, Nucleic Acid Extraction Kit, COVID-19 SARS-CoV-2 IgG/IgM Antibody Test Kit, Blood Gas Analyzer from Wuhan EasyDiagnosis has received EU CE marking, and there are more than 25 of our products are qualified for overseas sale.